Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $96.1 million.

  • Apellis Pharmaceuticals' Non-Current Assets rose 0.11% to $68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.0 million, marking a year-over-year increase of 0.11%. This contributed to the annual value of $96.1 million for FY2024, which is 329.02% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Non-Current Assets is $96.1 million, which was up 329.02% from $22.4 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Non-Current Assets registered a high of $96.1 million during FY2024, and its lowest value of $22.4 million during FY2023.
  • In the last 3 years, Apellis Pharmaceuticals' Non-Current Assets had a median value of $40.7 million in 2022 and averaged $53.1 million.
  • In the last 5 years, Apellis Pharmaceuticals' Non-Current Assets slumped by 44.96% in 2023 and then skyrocketed by 329.02% in 2024.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Non-Current Assets stood at $43.4 million in 2020, then skyrocketed by 33.06% to $57.7 million in 2021, then fell by 29.50% to $40.7 million in 2022, then crashed by 44.96% to $22.4 million in 2023, then spiked by 329.02% to $96.1 million in 2024.